However, no clear evidence of benefit for PTEN‐null cancer patients treated with PI3K inhibitors in clinics has been reported to date (Kim et al, 2017; Martin et al, 2017) and, despite the urgent need of a targeted treatment for this subset of poor prognosis patients, the molecular bases for the lack of efficacy of those therapies are still poorly understood. This evidence concerns the gene PTEN and cancer.